drugset / Trial / NCT05539521

Efficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Critically Ill Patients With Deep Sedation

NCT05539521

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of remimazolam besylate compared to propofol for sedation in critically ill patients with deep sedation.

Timeline

Start
2022-09-05
Primary completion
2023-02
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 3 mg/kg
Subject Remimazolam Small molecule 0.3 mg/kg

Indications

No indication recorded.